Bearish landing? Hong Kong stocks in the pharmaceutical sector collectively strengthen with wuxi apptec rising over 8%.

① How much impact did the biological safety legislation have on domestic pharmaceutical stocks previously? ② How do industry insiders view the subsequent development of the biological legislation?

cls.cnDec 8 21:40 ET

Hong Kong stock concept tracking | The biocontrol bill was not included in the latest version of NDAA. Institutions are bullish on the bottom opportunities in the CXO sector (with concept stocks attached).

On December 7, 2024, local time in the USA, the US Congressional Armed Services Committees in both the House and the Senate released the final agreement text of the 2025 National Defense Authorization Act (NDAA), which incorporates proposals from both chambers.

Zhitong FinanceDec 8 20:29 ET

Honkong stock market movement | CRO concept stocks collectively opened higher as the bioprotective legislation was not included in the final version of the NDAA by the U.S. Senate and House of Representatives.

CRO concept stocks opened higher collectively. As of the time of writing, wuxi bio (02269) increased by 13.03%, trading at 19.6 Hong Kong dollars; wuxi apptec (02359) rose by 11.72%, trading at 61 Hong Kong dollars; pharmaron (03759) climbed by 9.14%, trading at 16 Hong Kong dollars.

Zhitong FinanceDec 8 20:23 ET

Sinolink Securities: The favorable wind of medical policies arrives first, followed by innovation going abroad and performance reversal.

In 2025, Sinolink believes that the core investment opportunities in the pharmaceutical Sector will revolve around three main logics: 1) innovation going abroad; 2) demand recovery; 3) reversal of policy expectations.

Zhitong FinanceDec 8 18:31 ET

How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.

① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.

cls.cnDec 8 03:48 ET

[Brokerage Focus] CICC Securities: Several heavyweight domestically produced innovative drugs included in medical insurance, fund revenue and expenditure expected to improve.

Jingu Financial News | CMB International released a research report, stating that the MSCI Chinese medical index has cumulatively fallen by 17.6% since the beginning of the year, underperforming the MSCI China index by 30.1%. Benefiting from overseas interest rate cuts and domestic macroeconomic improvements, the medical industry, as a high elasticity sector, is expected to outperform the market. The new version of the medical insurance catalogue has been announced, with multiple heavyweight domestic innovative drugs included. The bank expects the price reduction of renewed varieties to be moderate, reflecting the strong support of the medical insurance fund for innovative drugs. In September and October this year, the balance of basic medical insurance (centralized fund) has significantly improved. As the policy focus shifts to stimulating the economy, the bank believes that the financial status of the medical insurance fund is

Jinwu Financial NewsDec 3 04:13 ET